Aptamer Group PLC
New OptimerĀ®+ platform delivers improved results compared to standard binders - Animal studies show good tolerance for therapeutic use
By Elric Langton | 27 February 2024
I have a financial interest in Aptamer Group.
Aptamer Groupās leap forward with its OptimerĀ®+ programme indeed marks a pivotal stride in the boundless expanse of the life sciences sector. This isnāt just a minor tweak; itās a significant evolution from their current OptimerĀ® offerings, promising binding reagents that cling to their targets with the tenacity of a bulldog. For the shareholders, this news is like a gust of fresh air sweeping through a stuffy room, hinting at a future brimming with potential riches.